Skip to main content

Closed

VYNE: VYNE Therapeutics Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+13.8% / yr

Operating margin-5367.6%

ROIC-98.9%

Financially safe

Stretched

Debt / equity0.00×

Interest coverage0.0×

Current ratio20.86×

VYNE Therapeutics Inc.

VYNENASDAQ Global Select·USD·Closed

VYNE Therapeutics Inc.

VYNENASDAQ·USD·Closed

$28.56

+0.00%

$28.56

+$0.00 (0.00%)

52W Range

24thpctl

Volume

6.17×avg

Mkt Cap

19.05MUSD

P/E

-0.0TTM

Div Yield

1.15%ann

52W Range

24thpctl

Volume

6.17×avg

Market Cap

19.05MUSD

P/E Ratio

-0.0TTM

Div Yield

1.15%ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings